NEW YORK, Oct. 31, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a
national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed
against Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares" or the "Company") and other defendants, related to alleged violations of
federal securities laws. If you purchased Antares securities between December 21, 2016 and
October 12, 2017, you are encouraged to a contact a Scott+Scott attorney at (844) 818-6982 for
additional information.
Antares is a specialty pharmaceutical company that develops pharmaceutical delivery systems, including needle-free and
mini-needle injector systems and transdermal gel technologies. Antares's product Xyosted has been among the Company's lead
product candidates.
The lawsuit claims that Antares made false and misleading statements and/or failed to disclose that Antares had provided
insufficient data to the U.S. Food and Drug Administration ("FDA") in connection with its New Drug Application ("NDA") for
Xyosted and had overstated the approval prospects for Xyosted.
On October 12, 2017, after the market closed, Antares disclosed that on October 11, 2017, it had received a letter from the FDA stating that the agency had "identified deficiencies
that preclude the continuation of the discussion of labeling and post marketing requirements/commitments" for Xyosted.
On this news, the price of Antares shares fell $1.41, or 37.80%, to close at $2.32 on October 13, 2017.
Then, on October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA
regarding the NDA for Xyosted, "indicat[ing] that the FDA cannot approve the NDA in its present form" due to concerns that
Xyosted "could cause a clinically meaningful increase in blood pressure" and noting concerns "regarding the occurrence of
depression and suicidality."
What You Can Do
If you purchased Antares securities between December 21, 2016 and October
12, 2017, inclusive, or if you have questions about this notice or your legal rights, please contact attorney Joe Pettigrew at (844) 818-6982, or at jpettigrew@scott-scott.com. Investors have until December 22, 2017, to move
for lead plaintiff.
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions
throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide
with offices in New York, London, Connecticut, California, and Ohio.
CONTACT:
Joe Pettigrew
Scott+Scott, Attorneys at
Law, LLP
(844) 818-6982
jpettigew@scott-scott.com
View original content:http://www.prnewswire.com/news-releases/scottscott-attorneys-at-law-llp-alerts-investors-to-the-filing-of-a-securities-class-action-against-antares-pharma-inc-atrs-300546420.html
SOURCE Scott+Scott, Attorneys at Law, LLP